Florida Financial Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Florida Financial Advisors LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,073 shares of the biopharmaceutical company’s stock after buying an additional 5,419 shares during the period. Gilead Sciences accounts for 0.9% of Florida Financial Advisors LLC’s investment portfolio, making the stock its 22nd largest position. Florida Financial Advisors LLC’s holdings in Gilead Sciences were worth $3,319,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ares Financial Consulting LLC acquired a new position in Gilead Sciences during the fourth quarter worth $28,000. Financial Consulate Inc. boosted its stake in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. boosted its stake in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares during the last quarter. BOCHK Asset Management Ltd acquired a new position in Gilead Sciences during the fourth quarter worth $31,000. Finally, Godfrey Financial Associates Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 53,000 shares of company stock valued at $7,075,670 in the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $134.43 on Monday. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29. The business’s fifty day simple moving average is $135.30 and its 200-day simple moving average is $134.20. The firm has a market cap of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter in the prior year, the company posted $1.81 EPS. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Analysts Set New Price Targets

GILD has been the topic of a number of recent research reports. Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Mizuho boosted their price objective on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Finally, Royal Bank Of Canada lowered their price objective on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research note on Friday, May 8th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.